GTHX has leaned way out over the front of their skis. Eg on this terminated trial they had not done a ph2, or indeed had any human data in this protocol or adjacent. They just relied on a speculative MOA w very sketchy data.
They are similarly ahead of themselves on the upcoming ph3 interim result. Huge change in protocol/population from ph2 and massively underpowered (it’s effectively two entirely separate trials in a single trial).
It’s a pity because it’s an interesting drug. It’s probably the single best poster child for the biotech aphorism that ‘even with a very good drug you need better than average management (similarly … vice versa)’.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.